Acquisition momentum FHI Clinical has recently expanded through acquisitions, notably the 2021 acquisition of TCD Global, indicating strategic growth and potential cross-sell opportunities to integrated CRO services and broader client bases.

Regional footprint Headquartered in Durham, NC with a global operations footprint and 75 countries of prior study experience, the company is positioned to pursue multinational trials and sponsors seeking local-to-global CRO support with regional expertise.

Immunotherapy focus Historical involvement in immunotherapy CRO capabilities and partnerships (IDRI, Sanaria) suggests strong capabilities for complex biologics and vaccine-related studies, offering a differentiator for sponsors in those modalities.

Mid-market positioning With revenue in the 50 to 100 million range and a staff size suitable for mid-market trial programs, FHI Clinical can target mid-sized sponsors seeking flexible, responsive CRO partnerships without managing a large enterprise vendor.

Tech-enabled agility Adoption of modern tech stack elements such as Salesforce and cloud infrastructure indicates an emphasis on streamlined study management, data handling, and customer engagement, enabling faster proposal cycles and scalable operations for sponsors.